IRUS Total

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study

File Description SizeFormat 
zwaa047.pdfPublished version722.99 kBAdobe PDFView/Open
Title: EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study
Authors: Ray, K
Molemans, B
Schoonen, WM
Giovas, P
Bray, S
Kiru, G
Murphy, J
Banach, M
De Servi, S
Gaita, D
Gouni-Berthold, I
Hovingh, GK
Jozwaik, JJ
Jukema, JW
Gabor Kiss, R
Kownator, S
Iversen, HK
Maher, V
Masana, L
Parkhomenko, A
Peeters, A
Clifford, P
Raslova, K
Siostrzonek, P
Romeo, S
Tousoulis, D
Vlachopoulos, C
Vrablik, M
Catapano, AL
Poulter, NR
DA VINCI study
Item Type: Journal Article
Abstract: Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52–56] achieved their risk-based 2016 goal and 33% (95% CI 32–35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate–high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination). Conclusion Gaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.
Issue Date: Nov-2021
Date of Acceptance: 6-Aug-2020
URI: http://hdl.handle.net/10044/1/83094
DOI: 10.1093/eurjpc/zwaa047
ISSN: 2047-4873
Publisher: SAGE Publications
Start Page: 1279
End Page: 1289
Journal / Book Title: European Journal of Preventive Cardiology
Volume: 28
Issue: 11
Copyright Statement: © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contactjournals.permissions@oup.com
Keywords: Cholesterol
DA VINCI study
Publication Status: Published
Online Publication Date: 2020-08-28
Appears in Collections:Faculty of Medicine
School of Public Health

This item is licensed under a Creative Commons License Creative Commons